Integral Diagnostics Ltd (IDX) reported a 50.1% increase in net profit after tax to AUD 47.4 million for the fiscal year ended June 30, 2026, driven by a 25.6% rise in revenue to AUD 788.7 million.
Operating earnings before interest, tax, depreciation and amortization (EBITDA) reached AUD 164.8 million, up from a pro forma AUD 150 million in the prior period, with margins expanding to 20.9% from 20.1%. Operating EBITA margins rose 120 basis points to 12.3%, while diluted earnings per share increased 23.6% year-over-year to AUD 0.126.
Free cash flow climbed 30.7% to AUD 106.4 million, reflecting an 82% cash conversion rate. Leverage ratios improved to 2.3 times EBITDA from 2.6 times, and liquidity headroom stood at AUD 117 million under committed debt facilities as of June 30, 2026.
The company declared a final dividend of AUD 0.06 per share, fully franked, bringing the total payout for FY2026 to AUD 0.093 per share. The dividend payout ratio was 73% of operating NPAT, within the group’s historical target range of 65% to 75%.
Jason Martinez, who took over as CEO on August 6, 2026, highlighted the integration of Capitol Health and the achievement of merger synergies exceeding AUD 14 million. He noted that FY2027 priorities would focus on execution and maximizing existing assets. Craig White, outgoing CFO, emphasized strong cash generation and confidence in the business outlook.
Shares of IDX rose 6.58% to AUD 2.43 following the earnings update, after closing at AUD 2.28 the previous day. The stock remains down about 30% year-to-date but is trading roughly 20.8% above its 52-week low and 20.8% below its 52-week high.
Operational metrics included serving 1.7 million patients and performing over 4 million examinations. The IDXt teleradiology network expanded to 143 radiologists, up 29 from the prior period. The company also opened new clinics in Wangaratta and Eastwood Private Hospital, relocated its Launceston clinic, and supported the opening of Maroochy Private Hospital in Queensland.
For FY2027, management expects operating EBITDA margins to exceed 21.0%, supported by initiatives such as MRI deregulation, national lung cancer screening programs, and the expansion of teleradiology services. A strategic review of New Zealand operations was also announced, with potential divestment options under consideration.
